Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,138 matching trials from the local directory fallback.
Filters: Condition: Lung Cancer Clear all
Active, not recruiting Phase 3 Interventional

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

NCT04428905
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Survivorship Care Plan, Telemedicine
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 15, 2026, 11:11 AM EDT
Active, not recruiting Not applicable Interventional

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

NCT05587972
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer, Lung Cancer, Multiple Myeloma
Interventions
survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 29, 2026, 9:27 PM EDT
Active, not recruiting Not applicable Interventional

Onco-primary Care Networking to Support TEAM-based Care

NCT04258813
View directory record Official record
Conditions
Blood Pressure, CVD - Cardiovascular Disease, Cancer, Cancer Colorectal, Cancer Ovaries, Cancer of Esophagus, Cancer of Head and Neck, Cancer of Liver, Cancer of Pancreas, Cancer of Prostate, Cancer, Breast, Cancer, Endometrial, Cancer, Renal Cell, Diabetes, Diabetes Mellitus, Hypercholesterolemia, Hypertension, Non Small Cell Lung Cancer
Interventions
Control, iGuide 2 Intervention (Tailored/Targeted), iGuide Intervention (Self-guided)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 79 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Aug 2, 2026, 2:13 AM EDT
Active, not recruiting Not applicable Interventional Results available

Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients

NCT03686007
View directory record Official record
Conditions
Caregiver, Stage I Lung Cancer AJCC v7, Stage IA Lung Cancer AJCC v7, Stage IB Lung Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage IIA Lung Cancer AJCC v7, Stage IIB Lung Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v7
Interventions
Informational Intervention, Media Intervention
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 16, 2026, 11:06 AM EDT
Active, not recruiting Not applicable Interventional

Oncology Episode Payment Model in Hawaii

NCT03523546
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Cancer Episode Payment Model (CEM)
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Jul 28, 2026, 12:01 PM EDT
Active, not recruiting Phase 2 Interventional

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
View directory record Official record
Conditions
Cutaneous Melanoma, Microsatellite Instability-High (MSI-H), Non-Small Cell Lung Cancer (NSCLC), Non-melanoma Skin Cancer (NMSC)
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 13, 2026, 4:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

NCT03830918
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Biological · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 15, 2026, 9:11 PM EDT
Active, not recruiting Phase 1 Interventional

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

NCT05239143
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Renal Cell Carcinoma
Interventions
P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2039
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 14, 2026, 3:48 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Abemaciclib, Erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
54
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 24, 2026, 8:40 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinician-Patient Communication in Lung Cancer Care

NCT02732834
View directory record Official record
Conditions
Lung Cancer
Interventions
2-hour empathic communication skills training, Audio recordings of clinical consultations, Patient Interview, Patient recruitment, Questionnaire, Standardized Patient Assessments, Training evaluation
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 29, 2026, 9:52 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662
View directory record Official record
Conditions
NSCLC, NSCLC Stage IV, NSCLC Stage IV Without EGFR/ALK Mutation, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Interventions
Standard of care, Sterotactic Body Radiotherapy/SBRT
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 29, 2026, 5:12 AM EDT
Active, not recruiting Phase 3 Interventional

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Cisplatin, Domvanalimab, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Zimberelimab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 27, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

NCT05340309
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
Biological · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 15, 2026, 5:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunvozertinib
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 29, 2026, 7:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Non Small Cell Lung Cancer
Interventions
IL-2, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 9, 2026, 8:18 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

NCT02779751
View directory record Official record
Conditions
Breast Cancer, Non Small Cell Lung Cancer
Interventions
Abemaciclib, Anastrozole, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Springdale, Arkansas • San Francisco, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 20, 2026, 2:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04743505
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
APL-101, Osimertinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Aug 2, 2026, 4:15 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Cervical Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Urothelial Carcinoma
Interventions
N-803 + Atezolizumab, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Docetaxel + Nivolumab, N-803 + Docetaxel + Pembrolizumab, N-803 + Durvalumab, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Nivolumab, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Pembrolizumab, N-803 + Pembrolizumab + PD-L1 t-haNK
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 1, 2026, 11:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

NCT05651022
View directory record Official record
Conditions
CRC (Colorectal Cancer), HCC - Hepatocellular Carcinoma, MSI-H Cancer, NSCLC Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Solid Tumor, Adult, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer)
Interventions
Decoy20, Tislelizumab
Drug
Lead sponsor
Indaptus Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 15, 2026, 9:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
View directory record Official record
Conditions
Limited-Stage Small Cell Lung Cancer
Interventions
HLX10, Placebo, Prophylactic Cranial Irradiation (PCI), Thoracic radiotherapy, carboplatin/cisplatin-etoposide
Drug · Radiation
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
31
States / cities
Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 13, 2026, 3:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810
View directory record Official record
Conditions
KRAS Activating Mutation, Non Small Cell Lung Cancer
Interventions
avutometinib and sotorasib, avutometinib and sotorasib and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 13, 2026, 4:19 PM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

NCT05902520
View directory record Official record
Conditions
Colorectal Cancer, Gynecologic Cancer, HNSCC, Lung Cancer, Melanoma, Urogenital Cancer
Interventions
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
Biological
Lead sponsor
AgonOx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 28, 2026, 7:21 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Taletrectinib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
20
States / cities
Beverly Hills, California • Glendale, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 3, 2026, 8:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Amrubicin, Lurbinectedin, Tarlatamab, Topotecan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 29, 2026, 1:35 AM EDT